Literature DB >> 1846038

Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine.

K M Chumakov1, L B Powers, K E Noonan, I B Roninson, I S Levenbook.   

Abstract

Production of live attenuated oral poliomyelitis vaccine (OPV) requires rigorous neurovirulence safety testing of each vaccine lot, currently carried out in monkeys. It has been reported that a change from 472-U to 472-C in the type 3 OPV RNA is associated with an increased histologic lesion score produced upon intraspinal inoculation of the mutant virus in monkeys. We have developed a method, based on polymerase chain reaction, for measuring the relative abundance of these mutant sequences directly in vaccine preparations and used this method to evaluate the proportion of 472-C in 40 different lots of type 3 OPV. Six vaccine lots that had failed the intraspinal monkey neurovirulence test contained a higher proportion of 472-C than all other lots that had passed this test. OPV type 3 virus containing 472-C was rapidly selected during serial passages in African green monkey kidney cells that are used for manufacturing of the vaccine. We have also found that the wild-type poliovirus type 3 strain Leon/37, from which the vaccine strain was originally derived, contained a mixture of 472-U and 472-C sequences. No other mutations in OPV type 3 RNA have been detected by similar assays at position 2034, also associated with attenuation, or at several other positions reported to be altered in some vaccine preparations. Our results suggest that molecular diagnostics may provide a supplement or a potential alternative to animal testing of live attenuated vaccines.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1846038      PMCID: PMC50777          DOI: 10.1073/pnas.88.1.199

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  16 in total

1.  Present position of immunization against poliomyelitis with live virus vaccines.

Authors:  A B SABIN
Journal:  Br Med J       Date:  1959-03-14

2.  Characteristics and genetic potentialities of experimentally produced and naturally occurring variants of poliomyelitis virus.

Authors:  A B SABIN
Journal:  Ann N Y Acad Sci       Date:  1955-09-27       Impact factor: 5.691

3.  Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine.

Authors:  S R Pollard; G Dunn; N Cammack; P D Minor; J W Almond
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

4.  Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine.

Authors:  G D Westrop; K A Wareham; D M Evans; G Dunn; P D Minor; D I Magrath; F Taffs; S Marsden; M A Skinner; G C Schild
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

5.  Differences in replication of attenuated and neurovirulent polioviruses in human neuroblastoma cell line SH-SY5Y.

Authors:  N La Monica; V R Racaniello
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

6.  Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia.

Authors:  R K Saiki; S Scharf; F Faloona; K B Mullis; G T Horn; H A Erlich; N Arnheim
Journal:  Science       Date:  1985-12-20       Impact factor: 47.728

7.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

8.  Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world.

Authors:  A B Sabin
Journal:  J Infect Dis       Date:  1985-03       Impact factor: 5.226

9.  Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome.

Authors:  D M Evans; G Dunn; P D Minor; G C Schild; A J Cann; G Stanway; J W Almond; K Currey; J V Maizel
Journal:  Nature       Date:  1985 Apr 11-17       Impact factor: 49.962

10.  Mapping of attenuating sequences of an avirulent poliovirus type 2 strain.

Authors:  E G Moss; R E O'Neill; V R Racaniello
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

View more
  40 in total

1.  Neurovirulence of type 1 polioviruses isolated from sewage in Japan.

Authors:  Hitoshi Horie; Hiromu Yoshida; Kumiko Matsuura; Miwako Miyazawa; Yoshihiro Ota; Takashi Nakayama; Yutaka Doi; So Hashizume
Journal:  Appl Environ Microbiol       Date:  2002-01       Impact factor: 4.792

2.  Quantitative mutant analysis of viral quasispecies by chip-based matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry.

Authors:  G Amexis; P Oeth; K Abel; A Ivshina; F Pelloquin; C R Cantor; A Braun; K Chumakov; A Brau
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

3.  Probability of fixation of an advantageous mutant in a viral quasispecies.

Authors:  Claus O Wilke
Journal:  Genetics       Date:  2003-02       Impact factor: 4.562

4.  High fidelity of yellow fever virus RNA polymerase.

Authors:  Konstantin V Pugachev; Farshad Guirakhoo; Simeon W Ocran; Fred Mitchell; Megan Parsons; Caroline Penal; Soheila Girakhoo; Svetlana O Pougatcheva; Juan Arroyo; Dennis W Trent; Thomas P Monath
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

5.  A mutation present in the amino terminus of Sabin 3 poliovirus VP1 protein is attenuating.

Authors:  J M Tatem; C Weeks-Levy; A Georgiu; S J DiMichele; E J Gorgacz; V R Racaniello; F R Cano; S J Mento
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

Review 6.  Poliomyelitis: eradication in sight.

Authors:  J L Melnick
Journal:  Epidemiol Infect       Date:  1992-02       Impact factor: 2.451

Review 7.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

8.  Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains.

Authors:  V Pliaka; Z Kyriakopoulou; D Tsakogiannis; I G A Ruether; C Gartzonika; S Levidiotou-Stefanou; A Krikelis; P Markoulatos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-05       Impact factor: 3.267

9.  Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccines.

Authors:  Alexander Neverov; Konstantin Chumakov
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

10.  High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis.

Authors:  M M Georgescu; F Delpeyroux; M Tardy-Panit; J Balanant; M Combiescu; A A Combiescu; S Guillot; R Crainic
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.